Minerva Neurosciences (NASDAQ:NERV) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06), MarketWatch Earnings reports.
NASDAQ:NERV opened at $7.19 on Tuesday. Minerva Neurosciences has a 1 year low of $5.80 and a 1 year high of $12.95.
Several equities analysts recently commented on the company. BidaskClub upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. ValuEngine upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research note on Tuesday, February 5th.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Further Reading: Dividend
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.